Transgenomic and Max-Planck Institute collaborate

collaboration for the development of a high-throughput genetic variation discovery system

11-Feb-2002
Transgenomic Inc. and the Berlin-Dahlem-based Max-Planck Institute for Molecular Genetics announced have entered into a multi-year collaboration for the development of a high-throughput genetic variation discovery system. Funded by the German National Genome Research Network (NGFN) and incorporating Transgenomic technology, the system developed will provide researchers with a better tool to attack large-scale genetic variation studies. Such studies are essential for developing associations between genetic variation and diseases, which in turn will allow biopharmaceutical companies to develop diagnostic tools and gene-based therapies. The work will be performed in the department of Prof. Hans Lehrach of the Institute. According to Dr. Richard Reinhardt, head of the scientific service group at the Institute, "Transgenomic technology is well suited for incorporation into such a system. It will facilitate the integration of the process, from sample preparation to sample introduction to analysis." Dr. Lehrach, director of the department of vertebrate genomics, added, "The Transgenomic technology should contribute to an eloquent solution for the high-throughput analysis needs, not only by its function but also by its economical nature. The cost per analysis should be very appealing." Collin D'Silva, CEO of Transgenomic, commented, "We are honored that the Max-Planck Institute has confidence in our ability to be an effective partner with them in developing this system. We are confident that our versatile technology will be a solid building block for its development." Transgenomic provides innovative research tools to the genomics segment of the Life Sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures